Results for “Security”

The UK Health Security Agency (UKHSA) intends to establish a Framework Agreement for the provision of Countermeasures and Preparedness products (the “Framework Agreement”). The Framework Agreement will be available for use by UKHSA and potentially other eligible public sector organisations such as the Ministry of Defence (MOD). The Framework Agreement will provide access to a range of pre-approved suppliers and their products. At this stage, it is intended that the Framework Agreement will comprise multiple lots including, but not limited to: - Antivirals - Antibiotics - Antitoxins - Antivenoms - Antidotes - Vaccines - Immunoglobulins - Intravenous Fluids (IV's) - ICU Medicines - Radiation Treatments - Medical Consumables (used in administering the medicines)* - Combined Needles and Syringes* *For the purposes of preliminary market engagement, we have included all products in scope of our portfolio. To confirm, recently awarded contracts will continue for their term.  The proposed scope and lotting structure will be explored further during the preliminary market engagement, with the final lotting structure confirmed in the UK 4 Tender Notice for this procurement. Suppliers will be awarded places on the Framework Agreement based on their ability to meet quality standards and deliver value for money. UKHSA is committed to working with suppliers who support Sustainability and Social Value objectives, and these elements are expected to form part of the award criteria, details of which will be set out in the tender documentation.

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Doxycycline 10 pack through this Request for Information (RFI), in accordance with the Procurement Act 2023.

Important: This event is intended to support engagement and information exchange between the Army's Directorate of Digital, Security and intelligence (D DSI) and industry. It is not a procurement activity, and attendance will not provide any organisation with a competitive advantage or preferential treatment in relation to any current or future commercial opportunities. The Dir DSI is bringing together industry partners with its senior leaders to shape the future of the digital environment for our war-fighters. We will cover: 1. The challenge: 1.1 How do we enhance 1.2 Security against emerging Threats 1.3 Information systems, intelligence, surveillance, and decision-making capabilities to the war-fighter 1.4 Cyber and electromagnetic activity on the battlefield 2. The Framework: 2.1 What are our Digital standards and how we conduct system integration 2.2 How we deliver Army digital services 3. Areas of opportunity: 3.1 Artificial Intelligence- enablement and governance 3.2 Sensor to effector network (ASGARD) 3.3 Building resilience across systems and operations On the day you will: 1. Gain insight into Army's future digital direction 2. Explore collaboration opportunities with key stakeholders 3. have the opportunity to take part in 1:1 sessions with senior leaders to discuss mutual priorities and challenges. 4. Hear directly from our 2* Director of Digital, Security and Intelligence (Dir DSI) This is an opportunity to understand where we are heading, and how industry can play a role in delivering the next generation of secure, resilient digital capability.

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Pralidoxime Chloride through this Request for Information (RFI), in accordance with the Procurement Act 2023. Suppliers wishing to be considered for inclusion in this procurement exercise must confirm their participation by the stated deadline. Suppliers who do not participate will not be included in the procurement process or considered for subsequent stages.

Continuous Improvement Action Tracker software to support the effective management, monitoring and reporting of Continuous Improvement Activities (CIAs) across ICS Commercial. The solution is intended to replace the current manual, Excel-based process with a more efficient, reliable and sustainable system.

The Council, on behalf of the Children's Commissioning Consortium Cyrum (4C's) is undertaking preliminary market engagement to identify suitably capable and experienced secure transport providers for the secure transportation of children and young people, on behalf of Welsh Local Authorities. Due to the anticipated value and infrequent nature of the requirement, the Council does not currently intend to establish a framework or award a public contract, in regards to the Procurement Act 2023 as part of this exercise. This market engagement is being carried out for information-gathering purposes only and is intended to help the Council better understand the availability, capability and experience within the market. The intention is to develop a list of capable suppliers for use by Welsh Local Authorities for secure transport provision. The provision of secure transportation services for children and young people must be delivered in a manner that safeguards and promotes the welfare of the child or young person receiving the service. Providers should note that this is a specialist service and will be expected to meet the requirements of the Welsh Government’s Reducing Restrictive Practices Framework. Providers will be required to have the following traing and practices in place: Safeguarding training and safeguarding procedures. Behaviour management training and approaches. Safe recruitment and robust employment checks. Safehold training and de-escalation techniques. Risk management, and safeguarding processes. Understanding and implementation of the restrictive practice framework. Ability to meet children's individual needs through appropriate resources, activities, and equipment.

The SIA are seeking providers of Lone Worker Applications for mobile devices to support the health, safety and wellbeing of staff who may be required to work alone, and in potentially vulnerable situations, as part of their job. This requirement is for an SIA user community of initially 150 colleagues, anticipated to increase to 200 over the course of the contract - The Mobile Device Application must; • Be available on iOS, Android or Windows, • Have an alert function which notifies users emergency contacts and 24/7 monitoring company once triggered, • Have a journey and meeting planner, which allows users to register journeys, pre-planned meetings/events and their estimated timings, • Have a welfare / check in feature prompting users to confirm safety at the conclusion of registered journeys, scheduled meetings, etc, • Have a live / real time GPS tracking facility to confirm user location to monitoring company if alert triggered • If an alert is activated the user's phone will live stream audio and video from the mobile device's microphone and camera to the monitoring company to enable staff to ascertain the user's situation and the appropriate support required. • The app should have a panic button feature, whether this be a button, or 'shake' for duress alarm activation • The system should be compatible with Bluetooth Smart buttons (including V.ALRT) - this can be used for raising an alarm and updating the handset's current location. • The application should have a solution for use on low data modes, or compatible for use in on GPRS or areas which don't have 3G/4G/5G signal. • Low battery life warnings - The Monitoring Solution must; • Be manned monitoring and response centre operating 24/7, • The 24/7 monitoring company will attempt to call user upon activation of an alert. • The 24/7 monitoring company will call Emergency services if required. • Individuals working at the monitoring centre must be vetted to a minimum standard of BPSS • An immediate emergency response solution should be offered upon, which must offer complete coverage of the UK - Service Desk The service desk acts as the primary user interface between the Buyer's IT users and the information system support function. The role of the service desk is to: • Take ownership of all calls made to it; • Ensure that the Buyers are provided with incident resolutions. The service desk may include, but will not be limited to, the provision of the following services: • A logical 'single point of contact' for all user issues • Telephone and email support • Accurate recording of all issues • Categorisation including issue type and severity levels • Issue prioritisation • Instigation of escalation procedures as appropriate • Direct and prompt resolution of issues • Providing timely and accurate information to users • Active ownership, tracking and management of all issues within scope - to ensure issues are resolved • To keep the caller updated of the status of any issue where they are unlikely to be resolved or completed within the agreed time • To update appropriate IT and user management of the status of all high priority and service affecting issues • Where necessary provide support to the repair process • Incident management and reporting

The purpose of this document is to enhance the Authority’s understanding of the marketplace and its options for sourcing for a potential future requirement. The issuance of this request for information (RFI) does not constitute a sourcing exercise nor will the Authority pay any costs incurred in the preparation of a response to this RFI. The UK Health Security Agency’s (UKHSA) key objectives for this RFI are: understand the ability of the marketplace to fulfil its requirements; refine the scope of the requirements to best align to the marketplace; and inform the Authority’s chosen route to market to best enable competition The key dates for this RFI are as follows: RFI Published: 30th June 2026 RFI Response: 14th July 2026 Should you have any questions or queries relating to this RFI, please use the Atamis portal’s messaging centre to direct your questions to us for a response. If a response is not received by the RFI response deadline this will have no impact on your ability to tender for the opportunity in the future. UKHSA will not enter into contracts on the basis of replies to this RFI.   Description of Scope of Requirements: The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure. Background: UKHSA is seeking to engage with the market to better understand supplier capability for the provision of lyophilisation (freeze-drying) services for X-ray irradiated pathogens to provide greater resilience and flexibility across use cases as part of UKHSA’s Pandemic Preparedness strategy. UKHSA requires support in developing optimal formulations and lyophilisation processes to ensure that irradiated, inactivated pathogens can be safely stored, handled, and distributed for diagnostic use and pandemic preparedness. Lyophilisation is required to enhance the long-term stability and usability of these materials, supporting strategic resilience and response capabilities. Requirements: We need the supplier to have: • Ability to handle irradiated, inactive viral and bacterial material in liquid medium • Ability to develop and optimise lyophilisation protocols including assessment of different stabilisation matrices • Appropriate quality system in place (at least ISO 9001) to ensure consistency and traceability • Provide product quality control (QC) testing of final product, including thermal stability and absence of contaminants. • Overall aim is to lyophilise up to 20 pathogens over the next 4 years o Estimated vial volume for lyophilisation is 0.3mL – 2mL o Estimated batch size for lyophilisation is 6 – 100mL o Estimated number of batches per year is 5 Should you wish to respond to this Request for Information, please complete the response questionnaire which is found at the following link: https://atamis-1928--prospend.vf.force.com/apex/CS_ContractPage?filters=&page=1&Preview=Yes&searchStr=&SearchType=Projects&sortStr=Alphabetical&uid=a07Pz00001jEyqdIAC&sfdcIFrameOrigin=https%3A%2F%2Fatamis-1928.lightning.force.com

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Botulinum Antitoxin Heptavalent (HBAT) through this Request for Information (RFI), in accordance with the Procurement Act 2023. The purpose of this exercise is to gather information on available products, supplier capability, and market conditions to inform a potential future procurement.

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Prussian Blue through this Request for Information (RFI), in accordance with the Procurement Act 2023. The purpose of this exercise is to gather information on available products, supplier capability, and market conditions to inform a potential future procurement.

*Notice V2* Updated link 25/06/2026 This is a Request for Information and not currently a tendering opportunity. The Authority is seeking to explore Hostile Vehicle Mitigation (HVM) solutions, specifically in the form of Vehicle Security Barriers (VSBs). This includes the potential establishment of a comprehensive through-life support including installations and maintenance contract, anticipated to span approximately 10 years, incorporating provisions for capability upgrades, technology refresh, and asset sustainment. The Authority welcomes input from subject matter experts and relevant suppliers to better understand the level of market interest and capability in delivering a requirement of this nature in the future. This also provides an opportunity for industry to offer feedback, highlight any concerns, and identify potential risks or constraints that may impact delivery.

The UK Health Security Agency (UKHSA) wishes to establish contracts for the provision of measles, mumps and rubella (MMR) vaccine

1. The purpose of this document is to enhance the Authority’s understanding of the marketplace and its options for sourcing for a potential future requirement. 2. The issuance of this request for information (RFI) does not constitute a sourcing exercise nor will the Authority pay any costs incurred in the preparation of a response to this RFI. 3. The UK Health Security Agency’s (UKHSA) key objectives for this RFI are: a. understand the ability of the marketplace to fulfil its requirements; b. refine the scope of the requirements to best align to the marketplace; and c. inform the Authority’s chosen route to market to best enable competition 4. The key dates for this RFI are as follows: 1. RFI Published: 12th June 2026 2. RFI Response: 10th July 2026 Description of Scope of Requirements: The UK Health Security Agency (UKHSA) is responsible for protecting every member of every community from the impact of infectious diseases, chemical, biological, radiological and nuclear incidents and other health threats. We provide intellectual, scientific and operational leadership at national and local level, as well as on the global stage, to make the nation's health secure. UKHSA sees access to oligonucleotide manufacturers as key to increasing the UK’s biosecurity, preparedness and resilience for infectious diseases. Oligonucleotides are a ubiquitous reagent used widely at many stages for research, development and use of diagnostics and countermeasures for infectious disease. Synthetic oligonucleotides are used widely as essential components of molecular diagnostic assays, sequencing methods and for development of serological assays, as well as critical reagents in the research, development and manufacture of new vaccines and therapeutics. The market for oligonucleotide supply in the UK, when you include use outside of infectious disease-related applications, is significant. UKHSA would like to understand the breadth and depth of oligonucleotide manufacturing capability in the UK and globally. This includes what oligonucleotides are already being manufactured, and to what design, what dependencies or bottlenecks exist, how these are being applied to make a product, and the existing and potential scale of manufacturing capacity. Although UKHSA is interested in understanding international manufacturing capability, UKHSA is specifically interested in improving onshore manufacturing capability for oligonucleotides and would encourage respondents to reflect any future intentions in the UK. This information will be used to inform UKHSA’s future approach to improve access to oligonucleotide products, and engagement with oligonucleotide manufacturers about UKHSA’s requirements. Should you wish to respond to this Request for Information, please complete the response questionnaire which is found at the following link: https://atamis-1928.my.salesforce-sites.com/ProSpend__CS_ContractPage?SearchType=Projects&uid=a07Pz00001dZ2lOIAS&searchStr=request+for+information&sortStr=Recently+Published&page=1&filters=&County=

This is a Preliminary Market Engagement (PME) Notice to inform and seek engagement with potential suppliers for Secure Offsite Storage of Records and Records Management Service for Health and Social Care for Northern Ireland (HSCNI). To this end, BSO Procurement and Logistics Service (PaLS) wish to engage with potential suppliers on behalf of HSCNI to obtain a market view of the potential requirements through a questionnaire. Any interested suppliers are required to submit their response through the eTendersNI secure messaging area Call for Tender (CfT) ref 6338997. All correspondence in relation to this PME will be communicated via the secure eTendersNI messaging area. Suppliers will be required to return answers to the questionnaire and any comments no later than 15:00 on Monday 22nd June 2026. Suppliers should also note that any interest shown does not constitute a commitment to participate in any future tendering exercise.

The UK Health Security Agency (UKHSA) is looking to gather information on diagnostics currently available on the UK market to test for Hantavirus or Hantavirus Andes strain specifically.   This is not a call for competition, but a market research activity aimed at gathering insights from suppliers to understand the current supplier landscape and market capabilities.   Interested suppliers are invited to complete the Microsoft form, included in the documentation available via the Atamis eSourcing portal (contract reference C451531), no later than 23:45 18/06/2026. Full details are included in the Preliminary Market Engagement Notice and questionnaire on the Portal https://atamis-1928.my.site.com/s/Welcome

The UK Health Security Agency (UKHSA) is looking to gather information on diagnostics currently available on the UK market to test for Ebola or Ebola Bundibugyo strain specifically.   This is not a call for competition, but a market research activity aimed at gathering insights from suppliers to understand the current supplier landscape and market capabilities.   Interested suppliers are invited to complete the Microsoft form, included in the documentation available via the Atamis eSourcing portal, no later than 23:45 17/06/2026. Full details are included in the Preliminary Market Engagement Notice and questionnaire on the Portal https://atamis-1928.my.site.com/s/Welcome

UKHSA is inviting suppliers to participate in a preliminary market engagement exercise for Smallpox Vaccine through this Request for Information (RFI), in accordance with the Procurement Act 2023. The purpose of this exercise is to gather information on available products, supplier capability, and market conditions to inform a potential future procurement.